Abstract 268P
Background
Sodium-glucose cotransporter 2 inhibitors (SGLT2I) have been suggested to reduce new-onset cancer amongst type-2 diabetes mellitus (T2DM) patients.
Methods
This real-world study aims to compare the risks of prostate cancer between SGLT2I and dipeptidyl peptidase-4 inhibitors (DPP4I) amongst T2DM patients.This was a retrospective population-based cohort study of prospectively recorded data on type-2 diabetes mellitus (T2DM) male patients prescribed either SGLT2I or DPP4I between January 1st 2015 and December 31st 2020 from Hong Kong. The primary outcome was new-onset prostate cancer. The secondary outcomes included cancer-related mortality and all-cause mortality. Propensity score matching (1:1 ratio) using the nearest neighbour search was performed and multivariable Cox regression was applied to compare the risk. A three-arm sensitivity analysis including the glucagon-like peptide-1 receptor agonist (GLP1a) cohort was conducted.
Results
This study included 42129 male T2DM patients (median age: 61.0 years old [SD: 12.2]; SGLT2I: n=17120; DPP4I: n=25009). After matching, the number of prostate cancers was significantly lower in SGLT2I users (n = 60) than in DPP4I (n = 102). SGLT2I use was associated with lower prostate cancer risks (HR: 0.45; 95% CI: 0.30-0.70) after adjustments than DPP4I. The results remained consistent in the sensitivity analysis. SGLT2I reduced the risks of prostate cancer prominently amongst patients who were older (age >65), patients with 2nd and 3rd quartile of HbA1c, concurrent metformin uses, and concurrent sulphonylurea uses. SGLT2I was associated with higher risks of prostate cancer amongst sulphonylurea non-users.
Conclusions
The real-world study demonstrated SGLT2I was associated with lower risks of new-onset prostate cancer after matching and adjustments compared to DPP4I. This result warrants further prospective studies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
87TiP - Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
Presenter: Mustafa Syed
Session: Poster Display
Resources:
Abstract
88TiP - A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling
Presenter: Nick Pavlakis
Session: Poster Display
Resources:
Abstract
93P - Efficacy and safety of fruquintinib (F) + best supportive care (BSC) vs placebo (P) + BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Presenter: Daisuke Kotani
Session: Poster Display
Resources:
Abstract
94P - Sidedness-dependent prognostic impact of gene alterations in metastatic colorectal cancer in the nationwide cancer genome screening project in Japan (SCRUM-Japan GI-SCREEN)
Presenter: Takeshi Kajiwara
Session: Poster Display
Resources:
Abstract
95P - Interim results of a prospective randomized controlled study to compare the clinical outcomes of total neoadjuvant therapy vs long course chemoradiotherapy in locally advanced carcinoma rectum
Presenter: Sandip Barik
Session: Poster Display
Resources:
Abstract
96P - Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study
Presenter: Jingdong Zhang
Session: Poster Display
Resources:
Abstract
97P - Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)
Presenter: Rui-Hua Xu
Session: Poster Display
Resources:
Abstract
98P - Real clinical impact of postoperative surgical complications after colon cancer surgery
Presenter: Toru Aoyama
Session: Poster Display
Resources:
Abstract
99P - Extended lymphadenectomy may not be necessary for MSI-H colon cancer patients after immunotherapy
Presenter: Rongxin Zhang
Session: Poster Display
Resources:
Abstract
100P - Identification of phenomic data in the pathogenesis of colorectal cancer: A UK biobank data analysis
Presenter: Shirin Hui Tan
Session: Poster Display
Resources:
Abstract